Journal profile · Medicine-Oncology
ImmunoOncology and Technology
ISSN 2590-0188 · Elsevier · United Kingdom
ImmunoOncology and Technology: fully open access; APC about USD 3,490; review about 153 days (submission to acceptance, publisher); 407 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
ImmunoOncology and Technology is published by Elsevier. By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses and Lung Cancer Treatments and Mutations, together about 57.2% of its articles. Its main subfields are Oncology and Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Immuno-Oncology and Technology (IOTECH) is sister journal to Annals of Oncology and ESMO Open and part of the European Society for Medical Oncology's portfolio of world-class journals. By publishing high quality original research articles, reviews, perspectives, technology explained papers, letters to the editor and editorials, IOTECH aspires to provide a forum for todays' leaders in the field of Immuno-Oncology.IOTECH is published quarterly and led by Co-Editors in Chief, Professor John Haanen and Professor Sherene Loi and an international team of expert Editors and Editorial Board members. It publishes pre-clinical and clinical studies covering natural and therapy-induced innate and adaptive immune responses against solid and haematological cancers. In addition, the journal has a strong focus on technological developments in Immuno-Oncology and seeks to highlight technological advances that decipher and improve clinical outcomes.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief Sherene LoiPublisher website
Editorial board by country: none in mainland China; most named United States 11, United Kingdom 9, Switzerland 7, Spain 2, Canada 2 (41 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine37.2%
- Immunotherapy and Immune ResponsesImmunology and Microbiology13.5%
- Lung Cancer Treatments and MutationsMedicine6.5%
- T-cell and B-cell ImmunologyImmunology and Microbiology5.3%
- CAR-T cell therapy researchMedicine4.1%
- Lung Cancer Research StudiesMedicine3.7%
- Cutaneous Melanoma Detection and ManagementMedicine3.3%
- Lung Cancer Diagnosis and TreatmentMedicine3.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Oncology | Q1 | 69/428 | 83rd |
| Immunology and Allergy | Q1 | 48/234 | 79th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
Other: Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 8.6LetPub ·
- CiteScore (publisher)
- 8.6Publisher website ·
- SJR 2026-06
- 1.88LetPub ·
- SNIP 2026-06
- 0.96LetPub ·
- h-index
- 23OpenAlex ·
- i10-index
- 54OpenAlex ·
- 2-year mean citedness
- 0.48OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 1,248 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 28 | 28 | 523 |
| 2025 | 407 | 407 | 580 |
| 2024 | 255 | 255 | 464 |
| 2023 | 229 | 229 | 321 |
| 2022 | 270 | 270 | 126 |
| 2021 | 19 | 19 | 72 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Publisher-reported review time from the journal's website
153 dayssubmission to acceptance · community reports about 29 weeks
The publisher's own definition applies; dates from this journal's articles in the last 24 months are not available yet, so the publisher's figure is used.
Figures by source
- Average review time (community reports)
- about 29 weeksLetPub ·
- Submission to acceptance
- 153 daysPublisher website ·
- Submission to publication (journal-reported)
- about 29 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,490 | Yes | CC BY-NC-ND | |
| OpenAlex | USD 3,340 / EUR 3,050 / GBP 2,670 / JPY 414,260 | — | — | |
| LetPub | EUR 2,750 | Yes | — | |
| Publisher website | USD 3,490 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Templates
- LaTeX
- Graphical abstract
- Optional
Article types accepted15, with length limits
- commentarysals for future avenues of exploration. Commentaries are generally commissioned by the Editors and should be a maximum of 1,500 words and have a maximum of ten …main text ≤ 1,500 words
- correspondenceOn topics of current interest or commenting upon material previously or simultaneously published in the journal. They should be limited to 500 words and may inc…main text ≤ 500 words
- editorialOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…main text ≤ 1,500 words
- editorialsEditorials (maximum 1,500 words)Length not stated
- meta-analysisOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…Length not stated
- narrative reviewOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…Length not stated
- original articleOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…main text ≤ 3,500 words
- original articlesOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Length not stated
- original researchOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…Length not stated
- research articleOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…Length not stated
- reviewOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…Length not stated
- review articleOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…main text ≤ 4,000 words
- review articlesReview Articles (maximum 4,000 words)Length not stated
- systematic reviewOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…Length not stated
- technology explained'Technology explained' articles should be approximately 2,000 words in lengthLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI in scientific writing
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. AI and AI-assisted technologies should not be used t…
Source ↗Publisher website ·- Authorship Authorship
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
Source ↗Publisher website ·- Conflicts of interest Declaration of Potential Conflicts of Interest
Any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications or opinions stated - including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition - should…
Source ↗Publisher website ·- Publication ethics
Ethics in publishing: refer to Elsevier's information on Ethics in publishing. Model summary
Please see our information on Ethics in publishing.
Source ↗Publisher website ·- License & copyright Copyright
Copyright: authors complete a License Agreement upon acceptance; third-party reuse determined by chosen user license. Model summary
Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (see more information on this). Permitted third party reuse of open access articles is determined by the author's choice of user license.Author rightsAs an author you (or your employer or institution) have certain rights to reuse your work. More information.
Source ↗Publisher website ·- Open access Open access
Please visit our Open Access page for more information about open access publishing in this journal.
Source ↗Publisher website ·- Peer review Peer Review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor'…
Source ↗Publisher website ·- Preprints Preprints
Preprints can be shared anywhere at any time; sharing will not count as prior publication. Model summary
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2590-0188
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
FAQ
Frequently asked questions about ImmunoOncology and Technology
How long does peer review take at ImmunoOncology and Technology?
The publisher reports about 153 days (submission to acceptance); authors report an average review time of about 29 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of ImmunoOncology and Technology?
According to the journal's author guidelines: Templates: LaTeX; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of ImmunoOncology and Technology based?
Of the 41 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (11), United Kingdom (9) and Switzerland (7). Counted from the institutions listed on the board page; for reference only.
Which databases index ImmunoOncology and Technology?
According to LetPub and DOAJ records, ImmunoOncology and Technology is indexed in Scopus and DOAJ. The journal's website also lists PubMed; that list has not been checked against each database.
Is ImmunoOncology and Technology open access, and what is the APC?
ImmunoOncology and Technology is a fully open-access journal. APC about USD 3,490.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .